BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2005) 78, 405-410
© 2005 British Institute of Radiology
doi: 10.1259/bjr/31803121
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harrington, K J
Right arrow Articles by Harmer, C L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harrington, K J
Right arrow Articles by Harmer, C L

Full Paper

Management of non-Hodgkin's lymphoma of the thyroid: the Royal Marsden Hospital experience

K J Harrington, MRCP, FRCR 1,2 V J Michalaki, MD 1 L Vini, FRCR 3 C M Nutting, MD, MRCP, FRCR 1,2 K N Syrigos, MD 1 R A'Hern, PhD 4 and C L Harmer, FRCP, FRCR 3

1 Head and Neck Cancer Unit, Royal Marsden Hospital, Fulham Road, London, 2 Institute of Cancer Research, Fulham Road, London, 3 Thyroid Unit, Royal Marsden Hospital, Fulham Road, London and 4 Department of Statistics, Royal Marsden Hospital, Fulham Road, London, UK

A retrospective review was conducted of patients treated for thyroid non-Hodgkin's lymphoma (TNHL) at the Royal Marsden Hospital between 1936 and 1996 to determine the effect of radiotherapy (RT) on outcome. 91 patients were identified from the Thyroid Unit Database. There were 77 females and 14 males with a median age of 65 years (range 22–87 years). RT was delivered according to two separate policies: (1) involved field radiotherapy (IFRT) to the thyroid bed and cervical lymph nodes; (2) extended field radiotherapy (EFRT) covering the thyroid bed, cervical and mediastinal lymph nodes. 89 patients received RT as part of definitive treatment following surgery, to a dose of approximately 40 Gy. 25 patients received IFRT and 64 patients EFRT. 27 patients received cytotoxic chemotherapy. 18 patients (72%) treated with IFRT died of TNHL with a median relapse free survival (RFS) of 10 months and a median overall survival (OS) of 21 months. In contrast, only 29 patients (46%) treated with EFRT died of TNHL with a median RFS of 76 months (p=0.01 for RFS with respect to IFRT and p=0.04 for OS). Significantly more patients treated with IFRT relapsed locally (52% vs 27%). There was no difference in the rates of systemic relapse (20% vs 22%). EFRT alone for Stage I, but not for Stage II disease, yielded acceptable rates of local control and disease free survival with doses of at least 40 Gy. These historical data strongly support the addition of combination chemotherapy to the treatment regimen in all patients with Stage II disease. Indeed, in recent years this has become the standard of care for all cases of thyroid lymphoma unless the histology is of marginal zone type (mucosa associated lymphoma tissue (MALT) lymphoma).




This article has been cited by other articles:


Home page
 Ann OncolHome page
N Niitsu, M Okamoto, N Nakamura, H Nakamine, M Bessho, and M Hirano
Clinicopathologic correlations of stage IE/IIE primary thyroid diffuse large B-cell lymphoma
Ann. Onc., July 1, 2007; 18(7): 1203 - 1208.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2005 by the British Institute of Radiology.